Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arvinas Holding Company LLC

8.60
+0.950012.42%
Post-market: 8.620.0200+0.23%19:56 EDT
Volume:3.19M
Turnover:26.35M
Market Cap:591.44M
PE:-3.11
High:8.64
Open:7.74
Low:7.61
Close:7.65
Loading ...

Arvinas down on investors’ read of Lilly data, says BTIG

TIPRANKS
·
12 Dec 2024

Arvinas Holding Company (ARVN) Receives a Buy from Evercore ISI

TIPRANKS
·
11 Dec 2024

Arvinas Price Target Maintained With a $87.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Dec 2024

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

Benzinga
·
11 Dec 2024

Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment

MT Newswires Live
·
10 Dec 2024

BRIEF-Arvinas And Pfizer Announce Initial Phase 1B Data From The Tactive-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium

Reuters
·
10 Dec 2024

Arvinas and Pfizer Announce Initial Phase 1B Data From the Tactive-U Sub-Study of Vepdegestrant in Combination With Abemaciclib at 2024 San Antonio Breast Cancer Symposium

THOMSON REUTERS
·
10 Dec 2024

Arvinas Inc - Vepdegestrant and Abemaciclib Show 62.5% Clinical Benefit Rate

THOMSON REUTERS
·
10 Dec 2024

Arvinas Inc - Combination Shows Consistent Safety Profile, No Significant Drug Interaction

THOMSON REUTERS
·
10 Dec 2024

Arvinas Inc - Recommended Phase 2 Dose Is 200 Mg Qd Vepdegestrant, 150 Mg Bid Abemaciclib

THOMSON REUTERS
·
10 Dec 2024

Arvinas initiated with a Buy at BTIG

TIPRANKS
·
10 Dec 2024

Press Release: Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

Dow Jones
·
27 Nov 2024

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

THOMSON REUTERS
·
26 Nov 2024

Arvinas Inc : Bmo Cuts Target Price to $88 From $90

THOMSON REUTERS
·
20 Nov 2024

Arvinas Inc : Leerink Partners Cuts Target Price to $62 From $64

THOMSON REUTERS
·
20 Nov 2024

Pfizer, Arvinas delay late-stage trial for breast cancer therapy

seekingalpha
·
19 Nov 2024

BRIEF-Arvinas Inc - 8-K SEC Filing

Reuters
·
19 Nov 2024

Arvinas Inc: Top-Line Data From Veritac-2 Phase 3 Second-Line Clinical Trial Anticipated in the First Quarter of 2025

THOMSON REUTERS
·
19 Nov 2024

Arvinas Inc - Veritac-2 Trial Completion Date Moved to January 2025

THOMSON REUTERS
·
19 Nov 2024

U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix

Reuters
·
19 Nov 2024